Gliomas are a major cause of cancer-related deaths in younger adults. About 7,000 patients harbor a common genetic mutation that affects the enzyme isocitrate dehydrogenase 1. This mutated enzyme, called mIDH1, can produce a molecule that can reprogram both the tumor cells and the environment in which they grow. The molecule, known as 2-hydroxyglutarate, can also circulate in the blood and reprogram immune cells in the bone marrow.
Engineered Nanoparticles Enhance Radiotherapy Effectiveness for Gliomas
Research highlights the role of engineered nanoparticles in enhancing the effectiveness of radiotherapy for gliomas, a significant cancer affecting younger adults. The study focuses on the genetic mutation mIDH1 and its impact on tumor behavior and immune response. This advancement in cancer treatment could have implications for healthcare in Iran, where cancer is a growing concern.
🏷️ Entities Mentioned
Translated from the original and edited for English readers. View original source →
Translation confidence: 100%